PT3139925T - Vmat2 inhibitors for the treatment of hyperkinetic movement disorders - Google Patents

Vmat2 inhibitors for the treatment of hyperkinetic movement disorders

Info

Publication number: PT3139925T
Authority: PT; Portugal
Prior art keywords: treatment; movement disorders; hyperkinetic movement; vmat2 inhibitors; vmat2
Prior art date: 2014-05-06

Application number

PT157244385T

Other languages

Portuguese (pt)

Original Assignee

Neurocrine Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-05-06

Filing date

2015-05-06

Publication date

2022-01-26

2015-05-06 Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc

2022-01-26 Publication of PT3139925T publication Critical patent/PT3139925T/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

PT157244385T 2014-05-06 2015-05-06 Vmat2 inhibitors for the treatment of hyperkinetic movement disorders PT3139925T (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201461989240P	2014-05-06	2014-05-06

Publications (1)

Publication Number	Publication Date
PT3139925T true PT3139925T (en)	2022-01-26

Family

ID=53264772

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT157244385T PT3139925T (en)	2014-05-06	2015-05-06	Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
PT211788823T PT3936130T (en)	2014-05-06	2015-05-06	VALBENAZINE DOSAGE REGIME FOR THE TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT211788823T PT3936130T (en)	2014-05-06	2015-05-06	VALBENAZINE DOSAGE REGIME FOR THE TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS

Country Status (24)

Country	Link
US (3)	US20170071932A1 (en)
EP (3)	EP4389227A3 (en)
JP (4)	JP6635945B2 (en)
KR (5)	KR20160147044A (en)
CN (3)	CN106456629A (en)
AU (1)	AU2015256012B2 (en)
CA (1)	CA2947736C (en)
CY (1)	CY1125058T1 (en)
DK (2)	DK3139925T3 (en)
ES (2)	ES2976207T3 (en)
FI (1)	FI3936130T3 (en)
HR (2)	HRP20220025T1 (en)
HU (2)	HUE057839T2 (en)
IL (1)	IL248745B (en)
LT (2)	LT3936130T (en)
MX (1)	MX387625B (en)
NZ (1)	NZ725826A (en)
PL (2)	PL3936130T3 (en)
PT (2)	PT3139925T (en)
RS (2)	RS65359B1 (en)
RU (1)	RU2753740C2 (en)
SI (2)	SI3936130T1 (en)
SM (2)	SMT202400199T1 (en)
WO (1)	WO2015171802A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX381258B (en)	2015-10-30	2025-03-12	Neurocrine Biosciences Inc	VALBENAZINE SALTS AND POLYMORPHS THEREOF.
US10160757B2 (en)	2015-12-23	2018-12-25	Neuroscrine Biosciences, Inc.	Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
WO2018001335A1 (en) *	2016-06-29	2018-01-04	苏州科睿思制药有限公司	Crystal forms of nbi-98854, preparation method therefor and use thereof
EP4400171A3 (en) *	2016-12-02	2024-09-11	Neurocrine Biosciences, Inc.	Use of valbenazine for treating schizophrenia or schizoaffective disorder
EP3568394A1 (en)	2017-01-10	2019-11-20	Sandoz AG	Crystalline valbenazine free base
EA201991786A1 (en)	2017-01-27	2020-01-16	Нейрокрин Байосайенсиз, Инк.	METHODS FOR INTRODUCING SOME VMAT2 INHIBITORS
WO2018153632A1 (en)	2017-02-27	2018-08-30	Sandoz Ag	Crystalline forms of valbenazine salts
WO2018164996A1 (en) *	2017-03-06	2018-09-13	Neurocrine Biosciences, Inc.	Dosing regimen for valbenazine
GB201705303D0 (en)	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
CN110678181A (en) *	2017-04-01	2020-01-10	阿德普蒂奥制药有限公司	Use of (+)-α-dihydrotetrabenazine in the treatment of dyskinesia
GB201705302D0 (en)	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
GB201705306D0 (en)	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
GB201705304D0 (en)	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
US20190111035A1 (en) *	2017-04-01	2019-04-18	Adeptio Pharmaceuticals Limited	Pharmaceutical compositions
GB201705305D0 (en) *	2017-04-01	2017-05-17	Adeptio Pharmaceuticals Ltd	Pharmaceutical compositions
CA3057548A1 (en) *	2017-04-01	2018-10-04	Adeptio Pharmaceuticals Limited	Pharmaceutical compositions
WO2018200605A1 (en) *	2017-04-26	2018-11-01	Neurocrine Biosciences, Inc.	Use of valbenazine for treating levodopa-induced dyskinesia
IL301770B2 (en)	2017-09-21	2024-06-01	Neurocrine Biosciences Inc	High dosage valbenazine formulation and compositions, methods, and kits related thereto
KR20250070134A (en)	2017-10-10	2025-05-20	뉴로크린 바이오사이언시즈 인코퍼레이티드	Methods for the administration of certain vmat2 inhibitors
MY198713A (en)	2017-10-10	2023-09-19	Neurocrine Biosciences Inc	Methods for the administration of certain vmat2 inhibitors
KR20210004939A (en) *	2017-11-08	2021-01-13	포시 파마슈티컬스 컴퍼니 리미티드	Ester of dihydrotetrabenazine
EP3733666B1 (en)	2017-12-26	2022-09-21	Crystal Pharmaceutical (Suzhou) Co., Ltd.	Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof
KR20210005623A (en)	2018-04-25	2021-01-14	신케이 테라퓨틱스 엘엘씨	Tetrabenazine transdermal delivery device
GB201808464D0 (en)	2018-05-23	2018-07-11	Adeptio Pharmaceuticals Ltd	Pharmaceutical compounds for use in treating huntington's disease
WO2019241555A1 (en)	2018-06-14	2019-12-19	Neurocrine Biosciences, Inc.	Vmat2 inhibitor compounds, compositions, and methods relating thereto
SG11202100303QA (en)	2018-08-15	2021-02-25	Neurocrine Biosciences Inc	Methods for the administration of certain vmat2 inhibitors
EP3860599B1 (en)	2018-10-04	2024-05-15	Adeptio Pharmaceuticals Limited	(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
MX2021013132A (en) *	2019-05-09	2021-11-25	Neurocrine Biosciences Inc	Methods for the administration of certain vmat2 inhibitors.
US10940141B1 (en) *	2019-08-23	2021-03-09	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2668689C (en) *	2006-11-08	2015-12-29	Neurocrine Biosciences Inc.	Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
WO2008060451A2 (en) *	2006-11-09	2008-05-22	New York University	Graded glass/zirconia/glass structures for damage resistant ceramic dental and orthopedic prostheses
GB2462611A (en)	2008-08-12	2010-02-17	Cambridge Lab	Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) *	2008-08-12	2011-03-03	Biovail Laboratories International (Barbados) S.R.L.	Pharmaceutical compositions
WO2011019956A2 (en) *	2009-08-12	2011-02-17	Biovail Laboratories International (Barbados) S.R.L.	Pharmaceutical compositions
EP2610254B1 (en)	2008-09-18	2015-11-25	Auspex Pharmaceuticals, Inc.	Deuterated benzoquinoline derivatives as inhibitors of vesicular monoamine transporter 2
CN104744456A (en) *	2010-06-01	2015-07-01	奥斯拜客斯制药有限公司	Benzoquinolone inhibitors of VMAT2
CN104684555A (en)	2012-09-18	2015-06-03	奥斯拜客斯制药有限公司	Formulation pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
RU2021128797A (en) *	2014-02-07	2021-11-26	Ньюрокрайн Байосайенсиз, Инк.	PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIPSYCHOTIC DRUG AND VMAT2 INHIBITOR AND THEIR APPLICATION

2015
- 2015-05-06 JP JP2016566238A patent/JP6635945B2/en active Active
- 2015-05-06 NZ NZ725826A patent/NZ725826A/en unknown
- 2015-05-06 SI SI201532006T patent/SI3936130T1/en unknown
- 2015-05-06 MX MX2016014429A patent/MX387625B/en unknown
- 2015-05-06 PL PL21178882.3T patent/PL3936130T3/en unknown
- 2015-05-06 CN CN201580023821.XA patent/CN106456629A/en active Pending
- 2015-05-06 KR KR1020167033765A patent/KR20160147044A/en not_active Ceased
- 2015-05-06 PT PT157244385T patent/PT3139925T/en unknown
- 2015-05-06 AU AU2015256012A patent/AU2015256012B2/en active Active
- 2015-05-06 KR KR1020227034399A patent/KR20220140647A/en not_active Ceased
- 2015-05-06 KR KR1020247001490A patent/KR20240011255A/en not_active Ceased
- 2015-05-06 KR KR1020257005033A patent/KR20250029267A/en active Pending
- 2015-05-06 SM SM20240199T patent/SMT202400199T1/en unknown
- 2015-05-06 HR HRP20220025TT patent/HRP20220025T1/en unknown
- 2015-05-06 WO PCT/US2015/029519 patent/WO2015171802A1/en not_active Ceased
- 2015-05-06 EP EP24157482.1A patent/EP4389227A3/en not_active Withdrawn
- 2015-05-06 LT LTEP21178882.3T patent/LT3936130T/en unknown
- 2015-05-06 RS RS20240380A patent/RS65359B1/en unknown
- 2015-05-06 RS RS20220008A patent/RS62782B1/en unknown
- 2015-05-06 ES ES21178882T patent/ES2976207T3/en active Active
- 2015-05-06 DK DK15724438.5T patent/DK3139925T3/en active
- 2015-05-06 HU HUE15724438A patent/HUE057839T2/en unknown
- 2015-05-06 DK DK21178882.3T patent/DK3936130T3/en active
- 2015-05-06 LT LTEPPCT/US2015/029519T patent/LT3139925T/en unknown
- 2015-05-06 CN CN202011483141.5A patent/CN112741836A/en active Pending
- 2015-05-06 SI SI201531799T patent/SI3139925T1/en unknown
- 2015-05-06 SM SM20220193T patent/SMT202200193T1/en unknown
- 2015-05-06 ES ES15724438T patent/ES2904526T3/en active Active
- 2015-05-06 CN CN202011483135.XA patent/CN112741835A/en active Pending
- 2015-05-06 EP EP21178882.3A patent/EP3936130B1/en active Active
- 2015-05-06 EP EP15724438.5A patent/EP3139925B1/en active Active
- 2015-05-06 KR KR1020207032879A patent/KR20200133003A/en not_active Ceased
- 2015-05-06 HU HUE21178882A patent/HUE066361T2/en unknown
- 2015-05-06 PL PL15724438T patent/PL3139925T3/en unknown
- 2015-05-06 FI FIEP21178882.3T patent/FI3936130T3/en active
- 2015-05-06 RU RU2016147523A patent/RU2753740C2/en active
- 2015-05-06 US US15/309,108 patent/US20170071932A1/en not_active Abandoned
- 2015-05-06 PT PT211788823T patent/PT3936130T/en unknown
- 2015-05-06 HR HRP20240459TT patent/HRP20240459T1/en unknown
- 2015-05-06 IL IL248745A patent/IL248745B/en unknown
- 2015-05-06 CA CA2947736A patent/CA2947736C/en active Active
2019
- 2019-10-02 JP JP2019181949A patent/JP2019218407A/en not_active Withdrawn
- 2019-12-03 US US16/701,339 patent/US20200101063A1/en not_active Abandoned
2020
- 2020-09-15 US US17/021,362 patent/US20210196702A1/en not_active Abandoned
2021
- 2021-09-22 JP JP2021153918A patent/JP2021191799A/en not_active Withdrawn
2022
- 2022-02-07 CY CY20221100104T patent/CY1125058T1/en unknown
2024
- 2024-07-29 JP JP2024122223A patent/JP2024153782A/en active Pending

Also Published As

Publication number	Publication date
WO2015171802A1 (en)	2015-11-12
RS62782B1 (en)	2022-01-31
EP3936130A1 (en)	2022-01-12
RS65359B1 (en)	2024-04-30
SMT202400199T1 (en)	2024-07-09
HRP20220025T1 (en)	2022-04-01
DK3139925T3 (en)	2021-12-20
RU2016147523A3 (en)	2018-12-28
KR20200133003A (en)	2020-11-25
KR20240011255A (en)	2024-01-25
FI3936130T3 (en)	2024-04-23
JP2017514850A (en)	2017-06-08
AU2015256012A1 (en)	2016-11-24
ES2904526T3 (en)	2022-04-05
PL3936130T3 (en)	2024-06-10
US20200101063A1 (en)	2020-04-02
MX387625B (en)	2025-03-18
US20210196702A1 (en)	2021-07-01
EP3139925B1 (en)	2021-12-01
ES2976207T3 (en)	2024-07-26
KR20160147044A (en)	2016-12-21
IL248745B (en)	2022-07-01
CN112741835A (en)	2021-05-04
CN106456629A (en)	2017-02-22
HUE066361T2 (en)	2024-07-28
SI3139925T1 (en)	2022-04-29
PT3936130T (en)	2024-04-17
CY1125058T1 (en)	2023-06-09
LT3139925T (en)	2022-01-25
LT3936130T (en)	2024-04-25
KR20250029267A (en)	2025-03-04
EP3936130B1 (en)	2024-02-14
NZ725826A (en)	2023-05-26
HUE057839T2 (en)	2022-06-28
PL3139925T3 (en)	2022-03-21
EP3139925A1 (en)	2017-03-15
HRP20240459T1 (en)	2024-06-21
KR20220140647A (en)	2022-10-18
EP4389227A3 (en)	2024-09-04
CA2947736A1 (en)	2015-11-12
CN112741836A (en)	2021-05-04
CA2947736C (en)	2023-04-18
JP6635945B2 (en)	2020-01-29
IL248745A0 (en)	2017-01-31
JP2021191799A (en)	2021-12-16
MX2016014429A (en)	2017-04-06
DK3936130T3 (en)	2024-03-25
SI3936130T1 (en)	2024-05-31
US20170071932A1 (en)	2017-03-16
SMT202200193T1 (en)	2022-07-21
RU2016147523A (en)	2018-06-08
AU2015256012B2 (en)	2020-07-23
EP4389227A2 (en)	2024-06-26
RU2753740C2 (en)	2021-08-23
JP2024153782A (en)	2024-10-29
JP2019218407A (en)	2019-12-26

Publication	Publication Date	Title
IL248745A0 (en)	2017-01-31	Vmat2 inhibitors for the treatment of hyperkinetic movement disorders
IL247515A0 (en)	2016-11-30	Cenicriviroc for the treatment of fibrosis
PT3169328T (en)	2022-05-27	Quinoline derivatives for the treatment of inflammatory diseases
IL247155A0 (en)	2016-09-29	Rapamycin for the treatment of lymphangioleiomyomatosis
IL248856A0 (en)	2017-01-31	New treatment
ZA201700183B (en)	2020-05-27	Acetylcholinesterase inhibitors for treatment of dermatological conditions
IL249502A0 (en)	2017-02-28	Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
PL3164394T3 (en)	2020-09-07	Gls1 inhibitors for treating diseases
SG11201609993YA (en)	2016-12-29	Treatment of immune disorders
IL246721B (en)	2018-12-31	Derivatives of 5-benzylisoquinoline for the treatment of cardiovascular diseases
HUE039750T2 (en)	2019-02-28	6-hydroxybuspirone for use in the treatment of movement disorders
PT3122349T (en)	2022-02-07	Compositions for the treatment of autodigestion
GB201416832D0 (en)	2014-11-05	Methods of treatment
SG11201702700UA (en)	2017-04-27	Methods for the treatment of peri-implantitis
PL2937084T3 (en)	2017-05-31	Method for the treatment of hypercholesterolemia
GB201412010D0 (en)	2014-08-20	Treatment of hypertransaminasemia
GB201417719D0 (en)	2014-11-19	New treatment
GB201408384D0 (en)	2014-06-25	New treatment